13. November 2009 07:42
Emergent BioSolutions Inc. announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.
[More]
12. November 2009 03:24
Got food poisoning? The cause might be bacterial spores, en extremely hardy survival form of bacteria, a nightmare for health care and the food industry and an enigma for scientists. Spore-forming bacteria, present almost everywhere in our environment, can also cause serious infectious diseases, such as tetanus, anthrax, and botulism.
[More]
22. October 2009 01:41
Cangene Corporation today reports financial results for the fiscal year ended July 31, 2009.
[More]
20. October 2009 04:38
Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.
[More]
d9a35ccf-7d13-4dd5-b69e-b39f57df172f|0|.0
Posted in: Business / Finance | Pharmaceutical News
Tags: Anthrax, Antibody, Botulism, Hepatitis B, Hepatitis C, Hospital, Prophylaxis, Smallpox, Transplant, Vaccine, Virus
19. October 2009 00:35
Emergent BioSolutions Inc. was pleased to sponsor the Security and Defence Agenda’s (SDA) roundtable discussion, “Raising Biopreparedness Levels in Europe,” which examined European efforts in preparing and reacting to various biological threats and the potential for European cooperation in these areas.
[More]
6. October 2009 07:21
Research and Markets (http://www.researchandmarkets.com/research/e70b48/the_future_of_the) has announced the addition of the "The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles" report to their offering.
[More]
5. October 2009 06:57
Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.
[More]
30. September 2009 08:51
Emergent BioSolutions Inc. announced today that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to further the development of one of Emergent’s advanced anthrax vaccine candidates known as dmPA7909.
[More]
25. September 2009 06:34
The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.
[More]
954d8bad-30f6-4904-8bea-62d8ee5d74ac|0|.0
Posted in: Pharmaceutical News
Tags: Allergy, Anthrax, Botulism, Cancer, CDC, Cervical Cancer, Cholera, Diphtheria, DNA, Haemophilus influenzae Type B, Hepatitis B, Hepatitis C, HIV/AIDS, Immunization, Influenza, Japanese Encephalitis, Leishmaniasis, Malaria, Measles, Mumps, Pandemic, Pfizer, Pneumococcal Disease, Polio, Rotavirus, Shingles, Smallpox, Tetanus, Tuberculosis, Tularemia, Typhoid Fever, Vaccine, Virus, West Nile Virus, Yellow Fever
25. September 2009 06:14
Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.
[More]
11. September 2009 05:52
This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The Study Analyzes the Market for 'Botulinum Toxin' by the Following Segments: Cosmetic, and Therapeutic (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity)
[More]
c14f5fea-2b82-4110-a290-500956ac7bf9|0|.0
Posted in: Pharmaceutical News
Tags: Botox, Botulism, Dysport, Dystonia, Education, Facial Wrinkles, Headache, Investment, Migraine, Overactive Bladder, Strabismus
21. June 2009 20:06
New structures of a botulism toxin interacting with a mimic of the nerve-cell protein it destroys suggest new ways to block this often-fatal interaction. Indeed, the mimic molecules have such high affinity for the toxin and bind to it so tightly that they themselves could possibly serve as anti-toxin drugs with further modification, the researchers said.
[More]
16. April 2009 22:40
Combating several human pathogens, including some biological warfare agents, may one day become a bit easier thanks to research reported by a University of Iowa chemist and his colleagues in the April 16 issue of the journal Nature.
[More]
16. April 2009 22:26
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
[More]
ad764bfe-a9c3-4ead-9487-1306d9003642|0|.0
Posted in: Medical Research News
Tags: Amino Acid, Anthrax, Antibiotic, Antiviral Drug, Botulism, Cellular Biology, DNA, Genetics, Lyme Disease, Pneumonia, Spectrometry, Syphilis, Tuberculosis
8. January 2009 22:46
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .
[More]
1f9816c2-881f-494c-8e65-c5f1779c4121|0|.0
Posted in: Drug Trial News
Tags: Adenovirus, Allergy, Anthrax, Antibody, Bird Flu, Botulism, Brain, CDC, Gene Therapy, Genetics, Immunology, Paralysis, Pediatrics, Toxicology, Tuberculosis, Vaccine, Virus
Subscribe